Science
Vyriad and Weizmann Institute of Science Enter Exclusive License Agreement for In Vivo Gene Delivery Technology
ROCHESTER, Minn. & REHOVOT, Israel, September 02, 2025--Exclusive license broadens Vyriad’s delivery portfolio with a novel viral targeting approach designed to preserve potency, while improving specificity
About this update from Weizmann Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2526,"height":348,"url":"https://media.zenfs.com/en/business-wire.com/3beffba8ed1460c6c297aa83c2034b89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hhEblQ2NvU3nVbTDBaVJqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3beffba8ed1460c6c297aa83c2034b89","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yiHdophYRoZcqskyh._fDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3beffba8ed1460c6c297aa83c2034b89","width":1200,"height":165}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Exclusive license with Yeda Research and Development Company, Weizmann Institute’s commercial arm, broadens Vyriad’s delivery portfolio with a novel viral targeting approach designed to preserve potency, while improving specificity","length":231,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Agreement brings together Weizmann’s discovery and Vyriad’s development expertise to expand strategies for safe, effective, and accessible in vivo therapies","length":156,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":387,"olType":false},{"type":"text","content":"ROCHESTER, Minn. & REHOVOT, Israel, September 02, 2025--(BUSINESS WIRE)--Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, and Yeda Research and Development Company, Ltd., the commercial arm of the Weizmann Institute of Science, today announced an exclusive license agreement for a novel viral vector targeting approach. The in vivo gene delivery technology, developed at the Weizmann Institute by professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin, can improve vector specificity without compromising potency.","length":616,"tagName":"p"},{"type":"text","content":"The licensed technology introduces a small, reversible adapter peptide that binds to a targeting protein on engineered viruses, temporarily masking the protein from native receptors, while presenting a new targeting domain. This method redirects the virus to selected cell types without altering its genetic sequence or ...